Afuresertib

Generic Name
Afuresertib
Brand Names
-
Drug Type
Small Molecule
Chemical Formula
C18H17Cl2FN4OS
CAS Number
1047644-62-1
Unique Ingredient Identifier
8739X25QI3
Background

Afuresertib has been used in trials studying the treatment of Cancer and Neoplasms, Haematologic.

Associated Conditions
-
Associated Therapies
-
Clinical Trials
Related News

Afuresertib +Sintilimab+Chemotherapy in Patients With Selected Solid Tumors That Resistance to Prior Anti-PD-1/PD-L1

First Posted Date
2022-05-20
Last Posted Date
2024-10-14
Lead Sponsor
Laekna Limited
Target Recruit Count
167
Registration Number
NCT05383482
Locations
🇨🇳

Zhongshan Hospital, Fudan University, Shanghai, Shanghai, China

🇨🇳

Beijing Cancer Hospital, Beijing, Beijing, China

🇨🇳

Chongqing Cancer Hospital, Chongqing, Chengdu, China

and more 2 locations

Study Evaluating Efficacy & Safety of Afuresertib Plus Fulvestrant in Patients w/ Locally Advanced or Metastatic HR+/HER2- Breast Cancer

Phase 3
Recruiting
Conditions
Breast Cancer
Interventions
Drug: Afuresertib
Drug: Afuresertib/placebo
First Posted Date
2021-04-20
Last Posted Date
2024-10-10
Lead Sponsor
Laekna Limited
Target Recruit Count
256
Registration Number
NCT04851613
Locations
🇺🇸

Providence St. Johns Health Center, Santa Monica, California, United States

🇺🇸

Virginia Cancer Specialists, Fairfax, Virginia, United States

🇺🇸

Piedmont Cancer Institute, Atlanta, Georgia, United States

and more 4 locations

Study With Afuresertib and Paclitaxel in Platinum Resistant Ovarian

First Posted Date
2020-05-05
Last Posted Date
2024-08-19
Lead Sponsor
Laekna Limited
Target Recruit Count
150
Registration Number
NCT04374630
Locations
🇺🇸

University of Massachusetts, Worcester, Massachusetts, United States

🇺🇸

University of Texas Health Science Center at Houston, Houston, Texas, United States

🇺🇸

US Texas Oncology, San Antonio, Texas, United States

and more 42 locations

Dose-Finding Study of Afuresertib Administered in Combination With Either Enzalutamide or Aibraterone

First Posted Date
2015-03-05
Last Posted Date
2016-10-06
Lead Sponsor
GlaxoSmithKline
Registration Number
NCT02380313

Study of Afuresertib Combined With Paclitaxel in Gastric Cancer

Phase 1
Completed
Conditions
Cancer
Interventions
Drug: Afuresertib
Drug: Paclitaxel
First Posted Date
2014-09-15
Last Posted Date
2017-04-11
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
29
Registration Number
NCT02240212
Locations
🇨🇳

Novartis Investigative Site, Taipei, Taiwan

A Study Conducted in Subjects With Relapsed/Refractory Multiple Myeloma (MM); to Determine Dose of Afuresertib in Combination With Carfilzomib (Part 1) and to Investigate the Safety, Pharmacokinetic and Clinical Activity of the Combination Compared With Carfilzomib Alone (Part 2)

Phase 1
Terminated
Conditions
Cancer
Interventions
Drug: Afuresertib
Drug: Carfilzomib
First Posted Date
2014-09-10
Last Posted Date
2016-05-04
Lead Sponsor
Novartis
Target Recruit Count
1
Registration Number
NCT02235740
Locations
🇺🇸

Novartis Investigative Site, Cary, North Carolina, United States

Study of Afuresertib Monotherapy in Japanese Relapsed Multiple Myeloma Patients

Phase 1
Terminated
Conditions
Neoplasms, Haematologic
Interventions
Drug: Afuresertib
First Posted Date
2014-06-30
Last Posted Date
2021-08-11
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
9
Registration Number
NCT02177682
Locations
🇯🇵

Novartis Investigative Site, Tokyo, Japan

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy